The experience of inhibitirs of tumor necrosis factor-α administration in patients with ankylosing spondilitis and psoriatic arthritis

Iaremenko O.B. 1, Ivashkovskyi O.I. 2, Fedkov D.L. 3

Summary. Summary. The article studies the efficiency and tolerability of the infliximab (INF) and adalimumab (ADA) biological therapy (BT) in 14 patients with ankylosing spondylitis (AS) and in 4 patients with psoriatic arthritis (PsA). After 3 months of the BT the AS activity considerably decreased and the functional state of the patients improved: the BASDAI and the BASFI dropped by 65%, the C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) dropped by 76.7% and 75.2% correspondingly. The changes remained stable during 9 months of the treatment, except for a slight ESR increase in the 9th month in comparison with the 3rd one. At that, the average ESR was within referential meaning. After 3 months of the INF treatment in the PsA patients with peripheral joints lesion there was a 90.1% decrease in the number of tender joints and there were no swollen joints. After 6 months there were neither tender nor swollen joints. After 3 and 6 months the psoriasis area and severity index (PASI) dropped by 92.8% and 80.8% correspondingly in comparison with the outgoing data. After 9 months of the treatment in the group of AS and PsA patients with a conditionally early BT initiation (less than 78 months from the disease onset) the CRP level decrease was considerably higher in comparison with a late BT initiation and there was also noticed a tendency to a more pronounced clinical effect. The therapy tolerance was high in 77.8% of cases, satisfactory in 22.2% of cases and there were no patients who refused completion of the therapy because of adverse events.

No Comments » Add your
Leave a comment